MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4

MicroRNAs in heart failure: from biomarker to target for therapy

(2016) Eline L. Vegter et al.   EUROPEAN JOURNAL OF HEART FAILURE

Heart Failure Therapies for End-Stage Chemotherapy–Induced Cardiomyopathy

(2016) Roy B. Mukku et al.   JOURNAL OF CARDIAC FAILURE

miR-30c and miR-181a synergistically modulate p53–p21 pathway in diabetes induced cardiac hypertrophy

(2016) Satish K. Raut et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Cardiac Nonmyocytes in the Hub of Cardiac Hypertrophy

(2015) T. Kamo et al.   CIRCULATION RESEARCH

Targeting microRNAs in Pathological Hypertrophy and Cardiac Failure

(2015) Dongchao Lv et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure

(2015) Carolina M. Greco et al.   Nature Reviews Cardiology

Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy

(2015) Xixian Li et al.   Oncotarget

The microRNA-15 family inhibits the TGFβ-pathway in the heart

(2014) Anke J. Tijsen et al.   CARDIOVASCULAR RESEARCH

Circulating Levels of Sirtuin 4, a Potential Marker of Oxidative Metabolism, Related to Coronary Artery Disease in Obese Patients Suffering from NAFLD, with Normal or Slightly Increased Liver Enzymes

(2014) Giovanni Tarantino et al.   Oxidative Medicine and Cellular Longevity

Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling

(2010) Eric Verdin et al.   TRENDS IN BIOCHEMICAL SCIENCES